PMID- 19530234
OWN - NLM
STAT- MEDLINE
DCOM- 20090908
LR  - 20211020
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Print)
IS  - 1545-5009 (Linking)
VI  - 53
IP  - 4
DP  - 2009 Oct
TI  - Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a 
      report from the CCG and COG.
PG  - 563-9
LID - 10.1002/pbc.22106 [doi]
AB  - BACKGROUND: The International Neuroblastoma Pathology Classification (INPC) was 
      the first to clearly define prognostic subgroups in ganglioneuroma (GN) and 
      ganglioneuroblastoma (GNB). PROCEDURE: Histopathology and tumor resectability of 
      552 GN/GNB cases from the Children's Cancer Group (CCG) and Children's Oncology 
      Group (COG) neuroblastoma studies were reviewed. The results were analyzed along 
      with clinical information and biological data of the cases. RESULTS: According to 
      the INPC, 300 tumors were classified into the Favorable Histology (FH) group and 
      252 were into the Unfavorable Histology (UH) group. Tumors in the FH group 
      included 43 ganglioneuroma-maturing (GN-M), 198 ganglioneuroblastoma-intermixed 
      (GNB-I), and 59 ganglioneuroblastoma-nodular, favorable subset (GNB-N-FS), and 
      were often (91%) resected completely by single or multiple surgical procedures. 
      Patients with the FH tumors had an excellent prognosis with no tumor-related 
      deaths. The UH group included ganglioneuroblastoma-nodular, unfavorable subset 
      (GNB-N-US) tumors. Patients with the UH tumors had a high incidence (53%) of 
      distant metastasis at the time of diagnosis, and their prognosis significantly 
      depended on clinical stage (5-year EFS: 80.1% for non-stage 4 patients; 16.7% for 
      stage 4 patients): Complete primary tumor resection was not beneficial to those 
      GNB-N-US patients, regardless of whether metastasis was present or not. MYCN 
      amplification was detected in four tumors in the FH group and six tumors in the 
      UH group. The majority (160/191, 84%) of GN-M and GNB-I tumors had a diploid 
      pattern determined by flow cytometry. CONCLUSIONS: Stringent application of the 
      INPC along with clinical staging was critical for prognostic evaluation of the 
      patients with this group of tumors.
FAU - Okamatsu, Chizuko
AU  - Okamatsu C
AD  - Department of Pathology and Laboratory Medicine, Childrens Hospital Los Angeles, 
      University of Southern California Keck School of Medicine, Los Angeles, 
      California 90027, USA.
FAU - London, Wendy B
AU  - London WB
FAU - Naranjo, Arlene
AU  - Naranjo A
FAU - Hogarty, Michael D
AU  - Hogarty MD
FAU - Gastier-Foster, Julie M
AU  - Gastier-Foster JM
FAU - Look, A Thomas
AU  - Look AT
FAU - LaQuaglia, Michael
AU  - LaQuaglia M
FAU - Maris, John M
AU  - Maris JM
FAU - Cohn, Susan L
AU  - Cohn SL
FAU - Matthay, Katherine K
AU  - Matthay KK
FAU - Seeger, Robert C
AU  - Seeger RC
FAU - Saji, Tsutomu
AU  - Saji T
FAU - Shimada, Hiroyuki
AU  - Shimada H
LA  - eng
GR  - U10 CA098413/CA/NCI NIH HHS/United States
GR  - U10 CA098413-02/CA/NCI NIH HHS/United States
GR  - U10 CA98413/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
RN  - 0 (MYCN protein, human)
RN  - 0 (N-Myc Proto-Oncogene Protein)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Oncogene Proteins)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Ganglioneuroblastoma/genetics/mortality/*pathology
MH  - Ganglioneuroma/genetics/mortality/*pathology
MH  - Humans
MH  - Infant
MH  - N-Myc Proto-Oncogene Protein
MH  - Neoplasm Staging
MH  - Nuclear Proteins/genetics
MH  - Oncogene Proteins/genetics
PMC - PMC2730988
MID - NIHMS123021
EDAT- 2009/06/17 09:00
MHDA- 2009/09/09 06:00
PMCR- 2010/10/01
CRDT- 2009/06/17 09:00
PHST- 2009/06/17 09:00 [entrez]
PHST- 2009/06/17 09:00 [pubmed]
PHST- 2009/09/09 06:00 [medline]
PHST- 2010/10/01 00:00 [pmc-release]
AID - 10.1002/pbc.22106 [doi]
PST - ppublish
SO  - Pediatr Blood Cancer. 2009 Oct;53(4):563-9. doi: 10.1002/pbc.22106.